BIODLINK-B

TOT Biopharm closed up 3.45% at HKD 3.60, opening higher and touching HKD 3.71 during the morning session before retreating to a low of HKD 3.58 in the afternoon, driven by progress in parent WuXi XDC's premium takeover offer. EPS remained negative for two straight quarters with loss widening over 30x YoY, as Q4 revenue tumbled 53% to HKD 144 million and net loss expanded to HKD 58 million, while the stock still trades 38.67% below its 52-week high of HKD 5.87 yet above its 20-day MA of HKD 3.41, with YTD decline of 14%.